CRLconf 0.99

reproxalap — CRL

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease

Event date

November 27, 2023

922 days ago

Sponsor runway

38 mo

$65.0M liquid

Evidence

“On November 27, 2023, Aldeyra announced that it had received a Complete Response Letter from the FDA. In the Complete Response Letter, the FDA stated that the NDA did not demonstrate "efficacy in treating ocular symptoms associated with dry eyes"”

Source: 8-K filed 2023-11-28View on EDGAR ↗0001193125-23-283679

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

3 insiders · 0 buys · 2 sells

Sell

2023-10-18

PERCEPTIVE ADVISORS LLC

10%+ Owner

306,499 @ $1.74$533K

Sell

2023-10-16

PERCEPTIVE ADVISORS LLC

10%+ Owner

2,450,000 @ $1.60$3.92M

Exercise

2023-09-07

Brady Todd C

President and CEO

32,953 @ $0.55$18K

Exercise

2023-09-07

Brady Todd C

President and CEO

48,021 @ $0.55$27K

Tax

2023-09-07

Brady Todd C

President and CEO

73,807 @ $7.22$533K

Exercise

2023-09-07

Brady Todd C

President and CEO

192,084 @ $0.55$106K

Exercise

2023-09-07

Phillips Gary M.

Director

5,437 @ $0.55$3K

Date	Insider	Action	Shares	Price	Value
2023-10-18	PERCEPTIVE ADVISORS LLC10%+ Owner	Sell	306,499	$1.74	$533K
2023-10-16	PERCEPTIVE ADVISORS LLC10%+ Owner	Sell	2,450,000	$1.60	$3.92M
2023-09-07	Brady Todd CPresident and CEO	Exercise	32,953	$0.55	$18K
2023-09-07	Brady Todd CPresident and CEO	Exercise	48,021	$0.55	$27K
2023-09-07	Brady Todd CPresident and CEO	Tax	73,807	$7.22	$533K
2023-09-07	Brady Todd CPresident and CEO	Exercise	192,084	$0.55	$106K
2023-09-07	Phillips Gary M.Director	Exercise	5,437	$0.55	$3K

← All catalysts for $ALDX